Several commercial samples of MDMB-CHMICA were found to exclusively contain the (S)-enantiomer based on vibrational and electronic circular dichroism spectroscopy and X-ray crystallography. An (S)-configuration for the tert-leucinate group is unsurprising since MDMB-CHMICA is likely synthesized from the abundant and inexpensive "L" form of the appropriate tert-leucinate reactant.
MDMB-CHMICA's main metabolic reactions comprise mono-hydroxylations and hydrolysis of the carboxylic ester function. In total, 31 metabolites could be identified in vivo.
71 serious adverse events, including 42 acute intoxications and 29 deaths (Germany (5), Hungary (3), Poland (1), Sweden (9), United Kingdom (10), Norway (1)) which occurred in 9 European countries between 2014 and 2016 have been associated with MDMB-CHMICA.
Side effects such as unconsciousness or coma, hyperemesis, nausea, seizures, convulsions, tachycardia, bradycardia, mydriasis, syncope, spontaneous urinating and defecating, shortness of breath, somnolence, respiratory acidosis, metabolic acidosis, collapse, lower limbs paralysis, chest pain, aggression and severe disturbance of behaviour were reported.
MDMB-CHMICA is illegal in Austria, Canada, China, Croatia, Denmark, Estonia, Finland, Germany, Greece, Hungary, Latvia, Lithuania, Louisiana, Luxembourg, Norway, Turkey, the UK,[dubious – discuss] Sweden and Switzerland.
In August 2016 the European Commission proposed a ban on MDMB-CHMICA across the European Union.
In 27 February 2017 the commission adopted an implementing act in banning MDMB-CHMICA, and Member States shall take the necessary measures to subject it to control measures and criminal penalties no later than by 4 March 2018.
^"MDMB-CHMICA". Southern Association of Forensic Scientists. Retrieved 2015.
^Banister, Samuel D.; Longworth, Mitchell; Kevin, Richard; Sachdev, Shivani; Santiago, Marina; Stuart, Jordyn; Mack, James B. C.; Glass, Michelle; McGregor, Iain S.; Connor, Mark; Kassiou, Michael (27 July 2016). "Pharmacology of Valinate and tert-Leucinate Synthetic Cannabinoids 5F-AMBICA, 5F-AMB, 5F-ADB, AMB-FUBINACA, MDMB-FUBINACA, MDMB-CHMICA, and Their Analogues". ACS Chemical Neuroscience. 7 (9): 1241-54. doi:10.1021/acschemneuro.6b00137. PMID27421060.
^Shevyrin, Vadim; Melkozerov, Vladimir; Nevero, Alexander; Eltsov, Oleg; Shafran, Yuri; Morzherin, Yuri; Lebedev, Albert T. (August 2015). "Identification and analytical characteristics of synthetic cannabinoids with an indazole-3-carboxamide structure bearing a N-1-methoxycarbonylalkyl group". Analytical and Bioanalytical Chemistry. 407 (21): 6301-6315. doi:10.1007/s00216-015-8612-7. PMID25893797.
^Andernach, Lars; Pusch, Stefan; Weber, Carina; Schollmeyer, Dieter; Münster-Müller, Sascha; Pütz, Michael; Opatz, Till (1 June 2016). "Absolute configuration of the synthetic cannabinoid MDMB-CHMICA with its chemical characteristics in illegal products". Forensic Toxicology. 34 (2): 344-352. doi:10.1007/s11419-016-0321-1.
^Langer, Nico; Lindigkeit, Rainer; Schiebel, Hans-Martin; Papke, Uli; Ernst, Ludger; Beuerle, Till (January 2016). "Identification and quantification of synthetic cannabinoids in "spice-like" herbal mixtures: update of the German situation for the spring of 2015". Forensic Toxicology. 34 (1): 94-107. doi:10.1007/s11419-015-0292-7.
^Maeda, Hideyuki; Nagashima, Erika; Hayashi, Yukiko K.; Kikura-Hanajiri, Ruri; Yoshida, Ken-ichi (2018). "MDMB-CHMICA induces thrashing behavior, bradycardia, and slow pressor response in a CB1- and CB2-receptor-dependent manner in conscious rats". Forensic Toxicology. 36 (2): 313-319. doi:10.1007/s11419-018-0405-1. ISSN1860-8965.
^Grigoryev, Andrej; Kavanagh, Pierce; Pechnikov, Alexandr (July 2016). "Human urinary metabolite pattern of a new synthetic cannabimimetic, methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate". Forensic Toxicology. 34 (2): 316-328. doi:10.1007/s11419-016-0319-8.
^Franz, Florian; Angerer, Verena; Moosmann, Bjoern; Auwärter, Volker (August 2016). "Phase I metabolism of the highly potent synthetic cannabinoid MDMB-CHMICA and detection in human urine samples". Drug Testing and Analysis. 9 (5): 744-753. doi:10.1002/dta.2049. ISSN1942-7611. PMID27504870.
^Hill, Simon L.; Najafi, Javad; Dunn, Michael; Acheampong, Paul; Kamour, Ashraf; Grundlingh, Johann; Blain, Peter G.; Thomas, Simon H. L. (13 September 2016). "Clinical toxicity following analytically confirmed use of the synthetic cannabinoid receptor agonist MDMB-CHMICA. A report from the Identification Of Novel psychoActive substances (IONA) study". Clinical Toxicology. 54 (8): 638-643. doi:10.1080/15563650.2016.1190980. ISSN1556-3650. PMID27251903.